Once-weekly insulin formulations promise improved treatment adherence through reduced injection frequency while maintaining glycemic efficacy in type 2 diabetes management. Recent completion of five large randomized controlled trials in 2025 provides sufficient data for comprehensive meta-analytic synthesis. In the study published in the Diabetes, Obesity, and Metabolism, the investigators systematically searched PubMed, Web of Science, ClinicalTrials.gov, and EU Clinical Trials Register through June 2025, identifying 16 randomized controlled trials evaluating once-weekly insulins against once-daily insulin or semaglutide comparators. 
Primary efficacy outcomes included HbA1c reduction, fasting plasma glucose change, continuous glucose monitoring-derived time-in-range, and time-above-range. Safety endpoints encompassed body weight variation, clinically significant or severe hypoglycemia incidence, and time-below-range. 
Superior Glycemic Efficacy Over Daily Regimens
Once-weekly insulins demonstrated statistically superior HbA1c reduction versus active comparators, achieving pooled mean difference of -0.12% (95% confidence interval -0.19 to -0.04, P=0.007). Continuous glucose monitoring metrics further confirmed ambulatory efficacy, with time-in-range extending 2.41% of total recording time (95% CI 1.13 to 3.69, P=0.002), reflecting clinically meaningful enhancement of daily glucose exposure.
Neutral Fasting Glucose and Hypoglycemia Profile
Fasting plasma glucose reductions proved comparable between once-weekly and comparator arms (-3.37 mg/dL, 95% CI -7.95 to 1.21, P=0.14), consistent with basal insulin pharmacodynamic equivalence. Clinically significant or severe hypoglycemia incidence remained statistically equivalent (pooled incidence rate ratio 1.04, 95% CI 0.79 to 1.28, P=0.75), confirming comparable safety across injection frequencies.
Weight Dynamics and Study Heterogeneity
Body weight changes showed general neutrality, though sensitivity analysis excluding IcoSema combination trials revealed modest increase (+0.33 kg, 95% CI 0.04 to 0.62, P=0.030). Meta-regression confirmed treatment effect consistency across once-weekly insulin formulations, trial durations exceeding 24 weeks, and prior insulin-naive versus experienced populations.
Clinical Implementation for Type 2 Diabetes Practice
Endocrinologists managing basal insulin-requiring type 2 diabetes gain evidence supporting once-weekly formulations as adherence-superior alternatives delivering incremental glycemic benefit without hypoglycemia penalty. Patient selection should prioritize injection-burdened individuals while monitoring weight trajectory, particularly avoiding fixed-ratio combinations in weight-sensitive cohorts. These findings strengthen guideline positioning of once-weekly insulins within progressive therapy intensification algorithms.